Search - tctmd.com

Displaying 161 - 180 of 300

Sort: Relevancy | Date

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Could PET Imaging Be the ‘Game Changer’ for Detecting and Predicting Bioprosthetic Valve Degeneration?

Michael O'Riordan

March 13, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

Advertisement

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

CHD Mortality Significantly Elevated in Patients With Severe FH

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Could PET Imaging Be the ‘Game Changer’ for Detecting and Predicting Bioprosthetic Valve Degeneration?

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Top News in Clinical Cardiology: 2018

Top News in Endovascular Therapy: 2018

Top News in Prevention: 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content